Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tomasello

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Journal of Biological Regulators and Homeostatic Agents|April 25, 2018
Clinical course of severe colitis: a comparison between Crohn’s Disease and ulcerative colitisE Sinagra, A Orlando, F Mocciaro, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 11, 2019
Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experienceM Ghidini, B M Donida, L Totaro, et al.
ESMO Open|August 9, 2024
Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner studyO Garrone, M Paccagnella, A Abbona, et al.
ESMO Open|October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONOD Rossini, A Boccaccino, A Sbrana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
European Journal of Histochemistry : EJH|February 3, 2012
Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapyG Tomasello, C Sciumé, F Rappa, et al.
Journal of Biological Regulators and Homeostatic Agents|January 3, 2014
Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insightsE Sinagra, G Tomasello, F Cappello, et al.
Journal of Biological Regulators and Homeostatic Agents|December 20, 2017
Colorectal cancer in patients with type 2 diabetes mellitus: a single-center experienceE Sinagra, V Guarnotta, D Raimondo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Journal of Biological Regulators and Homeostatic Agents|April 25, 2018
Clinical course of severe colitis: a comparison between Crohn’s Disease and ulcerative colitisE Sinagra, A Orlando, F Mocciaro, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 11, 2019
Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experienceM Ghidini, B M Donida, L Totaro, et al.
ESMO Open|August 9, 2024
Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner studyO Garrone, M Paccagnella, A Abbona, et al.
ESMO Open|October 24, 2021
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONOD Rossini, A Boccaccino, A Sbrana, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
European Journal of Histochemistry : EJH|February 3, 2012
Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapyG Tomasello, C Sciumé, F Rappa, et al.
Journal of Biological Regulators and Homeostatic Agents|January 3, 2014
Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insightsE Sinagra, G Tomasello, F Cappello, et al.
Journal of Biological Regulators and Homeostatic Agents|December 20, 2017
Colorectal cancer in patients with type 2 diabetes mellitus: a single-center experienceE Sinagra, V Guarnotta, D Raimondo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
Pageof 5